*4.4. Molecular Findings in the Study Cohort*

In our study, *LMNA* non-missense mutation carriers constituted nearly two thirds (62%) of the cohort. For comparison, in the study by Nishiuchi et al. [36], they constituted 75% of patients, whereas in the cohorts by Kumar et al. [10] and van Rijsingen et al. [7], they represented 42% and 45%, respectively. In the study by Wahbi et al. [37], carriers of non-missense variants were less common in the derivation sample (29%) but better represented in the smaller validation sample (46%).
